Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives Consensus Rating of “Buy” from Brokerages

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have been assigned a consensus rating of “Buy” from the seven analysts that are currently covering the stock, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $132.86.

Several equities analysts have weighed in on LNTH shares. Truist Financial raised their target price on Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a report on Thursday, February 27th. The Goldman Sachs Group started coverage on Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 target price on the stock. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Finally, JMP Securities restated a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th.

Lantheus Trading Down 4.9 %

LNTH opened at $104.62 on Wednesday. The stock has a market cap of $7.16 billion, a price-to-earnings ratio of 17.41 and a beta of 0.38. Lantheus has a 1 year low of $56.44 and a 1 year high of $126.89. The stock has a fifty day moving average price of $91.13 and a 200 day moving average price of $96.88.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The company had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. As a group, sell-side analysts forecast that Lantheus will post 6.01 earnings per share for the current fiscal year.

Insider Transactions at Lantheus

In other Lantheus news, Director James H. Thrall sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the transaction, the director now owns 33,207 shares of the company’s stock, valued at $3,146,695.32. This represents a 2.92 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Mary Anne Heino sold 53,107 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the sale, the director now owns 440,399 shares in the company, valued at approximately $41,551,645.65. This represents a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of LNTH. Wilmington Savings Fund Society FSB bought a new position in Lantheus in the third quarter worth $25,000. Kestra Investment Management LLC bought a new position in shares of Lantheus in the fourth quarter valued at about $27,000. Summit Securities Group LLC bought a new position in shares of Lantheus in the fourth quarter valued at about $37,000. UMB Bank n.a. raised its holdings in shares of Lantheus by 31.5% in the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after buying an additional 134 shares during the last quarter. Finally, World Investment Advisors LLC acquired a new stake in Lantheus in the third quarter worth about $60,000. 99.06% of the stock is owned by institutional investors.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.